Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Noninvasive Tests for NASH

Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests for NASH.
Stephen A. Harrison, MD, COL (Ret.), FAASLD
Released: July 7, 2020

Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests in NASH, including their use in:

  • Diagnosis of NASH patients with NAS ≥ 4 and fibrosis ≥ F2
  • Assessment of therapeutic response
  • Assessment of long-term patient outcomes

Download the slides from this podcast at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics/noninvasive-testing-now-and-in-the-future/slideset 

See more NASH topics at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics 

Acknowledgements

Provided by the American Gastroenterology Association.

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

Produced in collaboration with
Endocrine Society Logo
Supported by educational grants from
Allergan
Gilead Sciences
Intercept Pharmaceuticals, Inc.

Related Content

Rotonya Carr, MD, explores the evidence behind different diets in NAFLD/NASH: ketogenic diet, Mediterranean diet, and more for CCO

Rotonya Carr, MD Released: July 8, 2020

Hear CCO faculty Philip Newsome discuss the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Philip N. Newsome, PhD, FRCPE Released: February 12, 2020

CCO faculty Dr Juan Frias discusses the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Juan Pablo Frias, MD, FACE Released: February 5, 2020

Juan Frias and Philip Newsome: Learn about the agents in phase II and III clinical trials and their potential use in treatment.

Juan Pablo Frias, MD, FACE Philip N. Newsome, PhD, FRCPE Released: January 28, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?